Emmessar Biotech & Nutrition

Mumbai, India Founded: 1984 • Age: 42 yrs Listed
Herbal healthcare and nutritional products are manufactured.

About Emmessar Biotech & Nutrition

Emmessar Biotech & Nutrition is a publicly listed company based in Mumbai (India) founded in 1984. Herbal healthcare and nutritional products are manufactured. The company has 14 employees. Its Indian entity Emmessar Biotech And Nutrition Ltd reported revenue of β‚Ή2.41 Cr. Its focus areas include Traditional Nutraceuticals and Diversified.

Company details

Founded in 1984 in Mumbai, India, operations are focused on the herbal healthcare and nutrition sector. Creams and gels are produced to address skin conditions such as burns, scars, and irritations, alongside items for muscle recovery and general skin health. Natural ingredients are utilized in formulations, with an emphasis on therapeutic applications for holistic well-being. The domain ebnl.org is maintained for online presence.

  • Headquarters Mumbai, India
  • Employees 14
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website ebnl.org
  • Legal Name Emmessar Biotech & Nutrition Ltd.
Key Metrics
  • Market Cap
    ₹13.03 Cr

    EMMESSA · BSE

  • Share Price
    ₹28.90

    +10.94% today

  • Revenue
    ₹0.37 Cr

    FY 2025-26 · -39.3% YoY

  • EBITDA
    −₹1.35 Cr

    Margin -364.9%

  • Net Profit
    ₹0.45 Cr

    FY 2025-26 · +50.0% YoY

  • P/E (TTM)
    30.7x

    P/B 1.6x

  • ROE
    5.6%

    ROCE 6.7%

  • Employee Count
    14

Board of directors of Emmessar Biotech And Nutrition Ltd (Emmessar Biotech & Nutrition)

Emmessar Biotech And Nutrition Ltd is the primary company behind Emmessar Biotech & Nutrition. The board of Emmessar Biotech And Nutrition Ltd currently have 7 directors; the longest-serving is Srinivasa Raghavan Mathurakavi Ayyangar, appointed in 1992. 9 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Srinivasa Raghavan Mathurakavi Ayyangar
DIN 00090266
Managing Director17 Mar 199234 yrs 8 moEmmessar Biotech And Nutrition Ltd
Anuradha Srinivasa Raghavan
DIN 06557718
Director12 Aug 201313 yrs 3 moEmmessar Biotech And Nutrition Ltd
Sarada Srinivasa Raghavan
DIN 06641146
Director12 Aug 201313 yrs 3 moEmmessar Biotech And Nutrition Ltd
Jeyavel Balaiah Nadar
DIN 08163899
Whole-time director06 Feb 20215 yrs 9 moEmmessar Biotech And Nutrition Ltd
Milind Sitaram Desai
DIN 00326235
Director20 Oct 20224 yrsEmmessar Biotech And Nutrition Ltd
Veeraraghavan Ranganathan
DIN 00269682
Director27 Oct 20233 yrsEmmessar Biotech And Nutrition Ltd
Dinesh Kumar Deora
DIN 00148325
Director20 Mar 20242 yrs 7 moEmmessar Biotech And Nutrition Ltd

IPO & Listings of Emmessar Biotech & Nutrition

Emmessar Biotech & Nutrition is a publicly listed company on the BSE with ticker symbol EMMESSA in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date08 Sep 2000
  • Listed onBSE: 524768
  • Listed entityEmmessar Biotech & Nutrition Ltd.
  • Exchange sectorHealth technology
  • ISININE634B01016
  • Share price₹22.11 · 2026-10-14
  • Market capitalisation₹11.0 Cr
  • Price to earnings27.9
  • EPS (diluted, trailing year)₹0.79
  • Volume (last session)1,285

Financials of Emmessar Biotech & Nutrition

Exchange-reported figures of Emmessar Biotech And Nutrition Ltd, the listed company behind Emmessar Biotech & Nutrition (BSE: EMMESSA).

Financial Highlights

FY 2025-26 Β· Standalone
Revenue
₹0.37 Cr
-39.3% YoY
EBITDA
−₹1.35 Cr
-39.2% YoY
Profit After Tax
₹0.45 Cr
+50.0% YoY
Net Worth
₹8.12 Cr
+5.3% YoY
Total Assets
₹8.87 Cr
+5.2% YoY
Total Debt
Nil

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue0.370.610.561.020.366.993.40
Revenue growth-39.3%+8.9%-45.1%+183.3%-94.9%+105.6%-
EBITDA(1.35)(0.97)(1.08)(0.70)(0.91)0.86(0.67)
EBITDA margin-364.9%-159.0%-192.9%-68.6%-252.8%+12.3%-19.7%
Profit before tax0.590.940.810.960.922.270.74
Net profit0.450.300.750.500.471.460.97
Net profit margin+121.6%+49.2%+133.9%+49.0%+130.6%+20.9%+28.5%
EPS (β‚Ή)0.810.631.501.010.952.901.51
Balance sheet
Total assets8.878.438.247.476.886.405.03
Net worth8.127.717.416.676.175.704.27
Total debt0.000.000.110.080.000.000.00
Cash & bank7.326.876.185.194.582.471.88
Net working capital7.436.916.425.594.513.992.16
Cash flow
Cash from operations0.270.220.640.382.270.471.03
Cash from investing(0.26)(0.23)(0.64)(0.55)(2.61)0.01(1.06)
Cash from financing0.010.000.000.000.000.000.00
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue0.110.060.090.090.090.090.100.10
Revenue growth (YoY)+22.2%-33.3%-10.0%-10.0%-73.5%+12.5%--
Other income0.520.540.470.490.540.530.610.43
Total expenses0.430.410.460.430.460.370.420.38
EBITDA(0.32)(0.35)(0.37)(0.34)(0.37)(0.28)(0.32)(0.28)
EBITDA margin-290.9%-583.3%-411.1%-377.8%-411.1%-311.1%-320.0%-280.0%
Depreciation0.020.020.030.030.030.020.020.02
Interest0.000.000.000.000.000.000.000.00
Profit before tax0.180.170.070.120.140.230.270.13
Tax0.030.030.040.010.030.060.330.11

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 17 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue0.110.060.090.090.090.090.100.10
Revenue growth (YoY)+22.2%-33.3%-10.0%-10.0%-73.5%+12.5%--
Other income0.520.540.470.490.540.530.610.43
Total expenses0.430.410.460.430.460.370.420.38
EBITDA(0.32)(0.35)(0.37)(0.34)(0.37)(0.28)(0.32)(0.28)
EBITDA margin-290.9%-583.3%-411.1%-377.8%-411.1%-311.1%-320.0%-280.0%
Depreciation0.020.020.030.030.030.020.020.02
Interest0.000.000.000.000.000.000.000.00
Profit before tax0.180.170.070.120.140.230.270.13
Tax0.030.030.040.010.030.060.330.11
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue0.370.610.561.020.366.993.40
Revenue growth-39.3%+8.9%-45.1%+183.3%-94.9%+105.6%-
Other income2.042.011.991.751.921.471.47
Total expenses1.721.581.641.721.276.134.07
Employee cost0.000.930.960.840.770.640.58
EBITDA(1.35)(0.97)(1.08)(0.70)(0.91)0.86(0.67)
EBITDA margin-364.9%-159.0%-192.9%-68.6%-252.8%+12.3%-19.7%
Depreciation0.100.100.100.090.090.060.06
Interest0.000.000.000.000.000.000.00
Profit before tax0.590.940.810.960.922.270.74
Tax0.140.640.060.460.450.81(0.02)
Net profit0.450.300.750.500.471.460.97
Net profit margin+121.6%+49.2%+133.9%+49.0%+130.6%+20.9%+28.5%
EPS (β‚Ή)0.810.631.501.010.952.901.51
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital5.005.005.005.005.005.005.00
Reserves & surplus3.122.712.411.671.170.70(0.73)
Shareholders' funds (net worth)8.127.717.416.676.175.704.27
Secured loans0.000.000.110.080.000.000.00
Unsecured loans0.000.000.000.000.000.000.00
Total debt0.000.000.110.080.000.000.00
Total liabilities8.878.438.247.476.886.405.03
Assets
Gross block2.942.932.932.932.912.602.60
Net block1.721.811.902.002.081.861.92
Capital work in progress0.000.000.000.000.000.000.00
Investments0.010.010.010.010.010.010.01
Inventories0.100.120.090.140.070.071.15
Sundry debtors0.020.020.020.010.012.710.03
Cash & bank balances7.326.876.185.194.582.471.88
Loans & advances0.620.580.530.590.190.140.20
Total current assets8.067.596.825.934.855.393.26
Total current liabilities0.630.680.400.340.341.401.10
Net working capital7.436.916.425.594.513.992.16
Total assets8.878.438.247.476.886.405.03
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.010.010.010.180.530.050.08
Net cash from operating activities0.270.220.640.382.270.471.03
Net cash from investing activities(0.26)(0.23)(0.64)(0.55)(2.61)0.01(1.06)
Net cash from financing activities0.010.000.000.000.000.000.00
Net change in cash0.020.000.00(0.17)(0.34)0.48(0.03)
Closing cash7.326.876.185.194.582.471.88
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-39.3%+8.9%-45.1%+183.3%-94.9%+105.6%-
EBITDA growth-39.2%+10.2%-54.3%+23.1%-205.8%+228.4%-
PBT growth-39.4%+16.1%-15.6%+4.4%-59.5%+206.8%+164.3%
Net income growth+50.0%-60.0%+50.0%+6.4%-67.8%+50.5%-
Revenue CAGR (3Y)-28.7%+19.2%-56.9%-33.1%-17.0%+76.6%+9.2%
EBITDA CAGR (3Y)+25.1%+2.2%-+1.5%-1.1%--
Profitability & leverage
Net income margin+116.2%+49.2%+133.9%+49.0%+130.6%+20.9%+22.4%
Return on capital employed+6.7%+11.5%+10.3%+13.4%+14.2%+37.1%+17.1%
Return on net worth+5.6%+4.2%+10.7%+7.8%+8.1%+27.2%+19.3%
Debt / equity0.000.010.010.010.000.000.01
Long-term debt / equity0.000.000.000.000.000.000.00
Interest cover0.000.000.000.000.000.000.00
Efficiency & per share
Fixed asset turnover0.130.210.190.350.132.691.30
Inventory turnover3.365.814.879.715.1411.463.62
Debtors turnover18.5030.5037.33102.000.265.1097.14
EPS (β‚Ή)0.870.631.501.010.952.901.51
Dividend per share (β‚Ή)0.000.000.000.000.000.000.00
Book value per share (β‚Ή)16.2415.4314.8213.3412.3511.418.53

Web traffic of Emmessar Biotech & Nutrition

The website of Emmessar Biotech & Nutrition (ebnl.org) receives about 1.6K visits a month.

  • Monthly visits
    1.6K

    ▼ 3.4% vs previous month

Top companies in Traditional Health & Nutrition

3 companies that operate in the same segment as Emmessar Biotech & Nutrition (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Oral solid drug delivery systems are manufactured and developed.
1985Mumbai, Maharashtra, IndiaUSD 42.49 MUSD 72.52 M1,115
Generic, semi-solid, and liquid dosage forms are manufactured.
1990Bengaluru, Karnataka, IndiaUSD 508.93 M4,050
Specialty generic pharmaceuticals and APIs are manufactured and marketed.
1983Mumbai, Maharashtra, IndiaUSD 6.44 B19,801
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Emmessar Biotech & Nutrition

Premium access

Complete news archive for Emmessar Biotech Nutrition

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Emmessar Biotech & Nutrition

Emmessar Biotech & Nutrition was founded in 1984.

Emmessar Biotech & Nutrition is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

Emmessar Biotech & Nutrition has 14 employees.

The primary company behind Emmessar Biotech & Nutrition, Emmessar Biotech And Nutrition Ltd, reported revenue of β‚Ή2.41 Cr for FY 2026, down 39% year on year.

Founded in 1984 in Mumbai, India, operations are focused on the herbal healthcare and nutrition sector. Creams and gels are produced to address skin conditions such as burns, scars, and irritations, alongside items for muscle recovery and general skin health. Natural ingredients are utilized in formulations, with an emphasis on therapeutic applications for holistic well-being. The domain ebnl.org is maintained for online presence.

Yes, Emmessar Biotech & Nutrition is publicly traded on BSE under the ticker symbol EMMESSA.

Emmessar Biotech & Nutrition operates through Emmessar Biotech And Nutrition Ltd.

The legal entities of Emmessar Biotech & Nutrition currently have 8 directors, including Anuradha Srinivasa Raghavan, Sarada Srinivasa Raghavan, Jeyavel Balaiah Nadar and others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available